Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and angiotensin ii

rosiglitazone has been researched along with angiotensin ii in 38 studies

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's20 (52.63)29.6817
2010's17 (44.74)24.3611
2020's1 (2.63)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Filipek, B; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pańczyk, K; Pękala, E; Rapacz, A; Słoczyńska, K; Waszkielewicz, AM; Żelaszczyk, D; Żesławska, E1
Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H1
Amiri, F; Cohn, JS; Diep, QN; El Mabrouk, M; Endemann, D; Neves, MF; Schiffrin, EL; Virdis, A1
Chetty, R; Coppack, S; Harte, A; Katz, J; Kumar, S; McTernan, P; Smith, S1
Ahn, KO; Choi, YH; Chung, BH; Ito, S; Kim, J; Li, C; Lim, SW; Sugawara, A; Sun, BK; Yang, CW; Yang, JH; Yoon, KH1
Amiri, F; Benkirane, K; Diep, QN; El Mabrouk, M; Schiffrin, EL1
Amiri, F; Benkirane, K; Schiffrin, EL; Viel, EC1
Chen, J; Mehta, JL; Molavi, B1
Geng, DF; Jin, DM; Wang, JF; Wu, W; Wu, YM1
Gao, DF; Hao, GH; Ning, N; Niu, XL; Peng, N; Wang, NP; Wei, J1
Gaikwad, AB; Ramarao, P; Viswanad, B1
Averbukh, Z; Berman, S; Efrati, S; Ilgiyeav, E; Weissgarten, J1
Ahner, K; Boecking, W; Bramlage, P; Brosnihan, KB; Ferrario, CM; Jatzke, C; Kirch, W; Maywald, U; Oertel, R; Schindler, C1
Gao, DF; Hao, GH; Niu, XL; Wang, NP; Wei, J1
Bierhaus, A; Bozorgmehr, F; Dugi, K; Hamann, A; Humpert, PM; Ibrahim, Y; Kientsch-Engels, R; Kukudov, G; Morcos, M; Nawroth, PP; Oikomonou, D; Pfisterer, F; Rudofsky, G; Sayed, AA; Schlotterer, A; Schneider, J; Schwenger, V; van der Woude, F; Yard, B; Zeier, M1
Haider, DG; Jungbauer, A; Kapiotis, S; Mueller, M; Storka, A; Vojtassakova, E; Wolzt, M1
Gou, W; Ji, Y; Liu, J; Liu, N; Wang, Z1
Cockerill, GW; Deb, R; Dunkley, M; Gaze, D; Gnaneswaran, Y; Howe, F; Jones, A; Loftus, IM; Nasr, H; Thompson, MM; Torsney, E1
Chan, JY; Chan, SH; Chang, AY; Ho, YH; Wu, CA; Wu, KL1
Ji, YY; Liu, JT; Liu, N; Wang, ZD1
Burt, D; Camussi, G; Gruden, G; Miceli, I; Perin, PC; Tarabra, E1
Hu, D; Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R1
Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R; Zhi, H1
Ai, D; Guan, YF; Li, N; Niu, XL; Pang, W; Zhu, Y1
Cha, MJ; Choi, E; Ham, O; Hwang, KC; Jang, Y; Kim, IK; Kim, JS; Lee, SY; Lim, S; Song, BW; Song, H1
Cui, M; Han, CJ; Li, M; Liu, JT; Liu, XF; Mao, JJ; Pang, XM1
Cao, H; Cheng, YN; Dong, X; Dong, YN; Guo, XL; Sun, R; Wu, Y; Yang, KM; Yu, LG1
Cockerill, GW; Howe, F; Pirianov, G; Torsney, E1
Amin, R; Kariharan, T; Nanayakkara, G; Quindry, J; Viswaprakash, N; Zhong, J1
Auclair, M; Boccara, F; Capeau, J; Capel, E; Caron-Debarle, M; Guerci, B; Lascols, O; Vigeral, C; Vigouroux, C1
Bu, P; Cui, L; Hou, X; Liu, T; Shen, YH; Song, S; Zhang, Y1
Dong, X; Gao, D; Hao, G; Liu, Z; Meng, Z; Ning, N; Niu, X; Yang, G1
Liu, J; Pang, X; Wang, S; Wu, D; Zhang, X; Zhao, J1
Cui, X; Hong, L; Jin, HH; Li, X; Liu, LP; Liu, X; Zhang, B; Zhang, QG1
Chen, Z; Fu, R; Gao, J; Jia, L; Lu, J; Mao, J; Tian, L; Wang, L; Wei, L; Zhu, D1
Chen, YX; Sun, R; Wang, WD1
Fischer, C; Forstner, D; Gauster, M; Ghaffari-Tabrizi-Wizsy, N; Guettler, J; Juch, H; Kummer, D; Neuper, L; Nonn, O1

Trials

1 trial(s) available for rosiglitazone and angiotensin ii

ArticleYear
Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects.
    International journal of clinical pharmacology and therapeutics, 2008, Volume: 46, Issue:1

    Topics: Adult; Analysis of Variance; Angiotensin II; Double-Blind Method; Hand; Histamine; Humans; Hypoglycemic Agents; Insulin; Male; Nitroglycerin; Phenylephrine; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents; Veins

2008

Other Studies

37 other study(ies) available for rosiglitazone and angiotensin ii

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
    Bioorganic & medicinal chemistry, 2017, 01-15, Volume: 25, Issue:2

    Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Mice; Models, Molecular; Molecular Structure; Rats; Seizures; Structure-Activity Relationship

2017
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
    Circulation, 2002, Mar-12, Volume: 105, Issue:10

    Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Cells, Cultured; Chromans; Disease Models, Animal; Gene Expression; Heart; Heterozygote; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; Myocardium; Organ Size; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone

2002
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
    Circulation, 2002, May-14, Volume: 105, Issue:19

    Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Cell Cycle Proteins; Cell Division; Collagen; DNA; Drug Administration Schedule; Endothelium, Vascular; In Vitro Techniques; Inflammation; Injections, Subcutaneous; Lipids; Male; NF-kappa B; Pioglitazone; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Renin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Vascular Cell Adhesion Molecule-1; Vasoconstrictor Agents; Vasodilator Agents

2002
Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone.
    Circulation, 2005, Apr-19, Volume: 111, Issue:15

    Topics: Adipocytes; Angiotensin II; Antihypertensive Agents; Cells, Cultured; Drug Antagonism; Humans; Insulin; Obesity; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Up-Regulation

2005
Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005, Volume: 5, Issue:8

    Topics: Angiotensin II; Animals; Apoptosis; Cyclosporine; Diabetes Mellitus, Experimental; Glucose Tolerance Test; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Islets of Langerhans; Kidney; Osteopontin; Pancreatic Diseases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sialoglycoproteins; Thiazolidinediones; Transforming Growth Factor beta; Transforming Growth Factor beta1

2005
PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1.
    American journal of physiology. Heart and circulatory physiology, 2006, Volume: 290, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Carrier Proteins; Cell Proliferation; Intracellular Signaling Peptides and Proteins; Leucine; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Phosphatidylinositol 3-Kinases; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoproteins; Phosphoric Monoester Hydrolases; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Rosiglitazone; Signal Transduction; Thiazolidinediones; Thymidine

2006
Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:1

    Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Male; Mesenteric Arteries; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Signal Transduction; Thiazolidinediones; Vasoconstrictor Agents; Vasodilator Agents

2006
Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK.
    American journal of physiology. Heart and circulatory physiology, 2006, Volume: 291, Issue:2

    Topics: Angiotensin I; Angiotensin II; Animals; Blood Glucose; Cardiotonic Agents; Enzyme Inhibitors; Hemodynamics; Hypoglycemic Agents; Immunohistochemistry; Ligands; Male; Mitogen-Activated Protein Kinase 1; Myocardial Infarction; Myocardium; PPAR gamma; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones

2006
Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.
    International journal of cardiology, 2006, Oct-26, Volume: 113, Issue:1

    Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Collagen; Insulin; Ligands; Liver; Lung; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling

2006
Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis.
    Biochemical pharmacology, 2007, Jan-15, Volume: 73, Issue:2

    Topics: Angiotensin II; Animals; Apoptosis; Base Sequence; Blotting, Western; Cell Division; Connective Tissue Growth Factor; DNA Primers; Hypoglycemic Agents; Immediate-Early Proteins; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; PPAR gamma; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones

2007
PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
    Pharmacological research, 2007, Volume: 55, Issue:5

    Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; PPAR gamma; Prediabetic State; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Streptozocin; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents

2007
PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats.
    Nephron. Experimental nephrology, 2007, Volume: 106, Issue:4

    Topics: Angiotensin II; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Hypertension; Mesangial Cells; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones

2007
Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.
    British journal of pharmacology, 2008, Volume: 153, Issue:7

    Topics: Angiotensin II; Animals; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Matrix; Fibroblasts; Fibrosis; Gene Expression Regulation; Male; Myocardium; Plasminogen Activator Inhibitor 1; PPAR gamma; Prostaglandin D2; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1

2008
Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2008, Volume: 40, Issue:11

    Topics: Angiotensin II; Cell Nucleus; Cells, Cultured; Diabetic Nephropathies; Epithelial Cells; Gene Expression; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; NF-kappa B; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones; Tyrosine

2008
Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
    European journal of clinical investigation, 2008, Volume: 38, Issue:11

    Topics: Adipocytes; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blotting, Western; Endothelial Cells; Humans; Intra-Abdominal Fat; Lisinopril; Muscle, Skeletal; Nicotinamide Phosphoribosyltransferase; PPAR gamma; Receptor, IGF Type 1; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Umbilical Veins; Valine; Valsartan

2008
PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.
    Laboratory investigation; a journal of technical methods and pathology, 2009, Volume: 89, Issue:8

    Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Cell Survival; Cells, Cultured; Disease Models, Animal; Gene Expression; Gene Silencing; Hypoglycemic Agents; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Rats; Rats, Sprague-Dawley; RNA Interference; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Toll-Like Receptor 4; Vasculitis

2009
Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.
    Circulation, 2009, Jun-23, Volume: 119, Issue:24

    Topics: Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Blood Glucose; Body Weight; Cholesterol; Disease Models, Animal; E-Selectin; Humans; Hypercholesterolemia; Hypoglycemic Agents; Interleukin-6; Mice; Mice, Knockout; PPAR gamma; Receptors, Angiotensin; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha

2009
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension.
    Circulation research, 2009, Oct-23, Volume: 105, Issue:9

    Topics: Adenosine Triphosphate; Angiotensin II; Animals; Antioxidants; Blood Pressure; Blood Vessels; Catalase; Cell Respiration; Cyclic N-Oxides; Disease Models, Animal; Enzyme Inhibitors; Homeostasis; Humans; Hydrogen Peroxide; Hypertension; Imidazoles; Ion Channels; Male; Medulla Oblongata; Microinjections; Mitochondria; Mitochondrial Proteins; NADPH Oxidases; Onium Compounds; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphorylation; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Rosiglitazone; Spin Labels; Superoxide Dismutase; Superoxide Dismutase-1; Superoxides; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Transcription Factors; Transcriptional Activation; Transduction, Genetic; Uncoupling Protein 2; Up-Regulation

2009
[Inhibitory effects of rosiglitazone on angiotensin II-induced toll-like receptor 4 expression and myeloperoxidase activity in RAW264.7 cells].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2009, Volume: 29, Issue:9

    Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Macrophages; Mice; Peroxidase; Rosiglitazone; Thiazolidinediones; Toll-Like Receptor 4

2009
Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.
    American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cell Proliferation; Cells, Cultured; Diabetic Nephropathies; Down-Regulation; Humans; Membrane Proteins; Podocytes; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Rosiglitazone; Stress, Mechanical; Thiazolidinediones; Up-Regulation

2010
The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.
    Cell biochemistry and function, 2010, Volume: 28, Issue:1

    Topics: Angiotensin II; Animals; Biphenyl Compounds; Cardiomegaly; Cholesterol, Dietary; Hypercholesterolemia; Irbesartan; Male; Myocardium; PPAR gamma; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones

2010
Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.
    Cardiovascular diabetology, 2011, Jan-26, Volume: 10

    Topics: Angiotensin II; Animals; Aortic Diseases; Atherosclerosis; Blotting, Western; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Hypercholesterolemia; Immunohistochemistry; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Radioimmunoassay; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors

2011
Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes.
    Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:6

    Topics: Angiotensin II; Animals; Cardiomegaly; Cell Line; Epoxide Hydrolases; Gene Expression Regulation, Enzymologic; Humans; Ligands; Male; Mice; Mice, Knockout; Myocytes, Cardiac; PPAR gamma; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vasodilator Agents

2011
Anti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway.
    Cell biology international, 2012, Mar-01, Volume: 36, Issue:3

    Topics: Angiotensin II; Animals; Cell Proliferation; Muscle, Smooth, Vascular; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; TOR Serine-Threonine Kinases

2012
Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2012, Volume: 61, Issue:9

    Topics: Angiotensin I; Angiotensin II; Anti-Inflammatory Agents; Aorta; C-Reactive Protein; Cells, Cultured; Endothelial Cells; Humans; Mitogen-Activated Protein Kinases; PPAR gamma; Reactive Oxygen Species; RNA, Messenger; Rosiglitazone; Thiazolidinediones

2012
Inhibition of PTEN expression and activity by angiotensin II induces proliferation and migration of vascular smooth muscle cells.
    Journal of cellular biochemistry, 2013, Volume: 114, Issue:1

    Topics: Adenoviridae; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Cell Movement; Cell Proliferation; Focal Adhesion Kinase 1; Gene Expression Regulation; Losartan; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Rosiglitazone; Signal Transduction; Sulfones; Thiazolidinediones; Tissue Culture Techniques; Transduction, Genetic; Vasodilator Agents

2013
Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms.
    Atherosclerosis, 2012, Volume: 225, Issue:1

    Topics: Angiotensin II; Animals; Aortic Aneurysm; Aortic Rupture; Down-Regulation; JNK Mitogen-Activated Protein Kinases; Mice; Phosphorylation; Rosiglitazone; Signal Transduction; Thiazolidinediones; Toll-Like Receptor 4

2012
PPARγ activation improves the molecular and functional components of I(to) remodeling by angiotensin II.
    Current pharmaceutical design, 2013, Volume: 19, Issue:27

    Topics: Angiotensin II; Animals; Atrial Remodeling; Cardiotonic Agents; Cells, Cultured; Diabetic Cardiomyopathies; Down-Regulation; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Myocytes, Cardiac; Oxidative Stress; Potassium Channels, Voltage-Gated; PPAR gamma; Protein Transport; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Rosiglitazone; Thiazolidinediones; Ventricular Remodeling

2013
Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:4

    Topics: Adult; Aged; Amino Acid Sequence; Angiotensin II; Anilides; Animals; Case-Control Studies; Enzyme Activation; Female; Fibroblasts; Genetic Predisposition to Disease; HEK293 Cells; Humans; Hypertension; Inflammation Mediators; Leukocytes, Mononuclear; Lipodystrophy, Familial Partial; Male; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Muscle, Smooth, Vascular; Mutation; Myocytes, Smooth Muscle; Oxidative Stress; Phenotype; PPAR gamma; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA Interference; Rosiglitazone; Severity of Illness Index; Skin; Thiazolidinediones; Transfection; Young Adult

2013
PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.
    European journal of pharmacology, 2013, Sep-05, Volume: 715, Issue:1-3

    Topics: Angiotensin II; Animals; Cell Differentiation; Cell Proliferation; Cell Survival; Collagen Type I; Collagen Type III; Cyclin D1; Fibroblasts; JNK Mitogen-Activated Protein Kinases; Myocardium; Myofibroblasts; Phenotype; PPAR gamma; Protein Multimerization; Protein Structure, Quaternary; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factor AP-1; Transforming Growth Factor beta1

2013
Rosiglitzone suppresses angiotensin II-induced production of KLF5 and cell proliferation in rat vascular smooth muscle cells.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Angiotensin II; Anilides; Animals; Blood Pressure; Body Weight; Cell Proliferation; Cells, Cultured; Cyclin D1; Gene Expression Regulation; Hypoglycemic Agents; Kruppel-Like Transcription Factors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Phosphorylation; PPAR gamma; Prostaglandin D2; Protein Kinase C; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones

2015
Rosiglitazone attenuates angiotensin II-induced C-reactive protein expression in hepatocytes via inhibiting AT1/ROS/MAPK signal pathway.
    International immunopharmacology, 2016, Volume: 31

    Topics: Angiotensin II; Animals; C-Reactive Protein; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Hepatitis; Hepatocytes; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Rosiglitazone; Signal Transduction; Thiazolidinediones

2016
Ginsenoside Re prevents angiotensin II-induced gap-junction remodeling by activation of PPARγ in isolated beating rat atria.
    Life sciences, 2017, Dec-01, Volume: 190

    Topics: Angiotensin II; Anilides; Animals; Blotting, Western; Connexin 43; Connexins; Dose-Response Relationship, Drug; Down-Regulation; Female; Gap Junction alpha-5 Protein; Gap Junctions; Ginsenosides; Heart Atria; Male; Matrix Metalloproteinase 2; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazolidinediones

2017
Rosiglitazone Inhibits Angiotensin II-Induced Proliferation of Glomerular Mesangial Cells via the Gαq/Plcβ4/TRPC Signaling Pathway.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 44, Issue:6

    Topics: Angiotensin II; Animals; Calcium; Cell Line; Cell Proliferation; GTP-Binding Protein alpha Subunits, Gq-G11; Mesangial Cells; Phospholipase C beta; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; TRPC Cation Channels

2017
PPARγ agonist rosiglitazone alters the temporal and spatial distribution of inflammation during abdominal aortic aneurysm formation.
    Molecular medicine reports, 2018, Volume: 18, Issue:3

    Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Aortic Rupture; Apolipoproteins E; Disease Models, Animal; Inflammation; Male; Mice; Mice, Knockout; Models, Biological; PPAR gamma; Rosiglitazone; Th2 Cells; Thiazolidinediones; Vasodilator Agents

2018
Candesartan Does Not Activate PPARγ and Its Target Genes in Early Gestation Trophoblasts.
    International journal of molecular sciences, 2022, Oct-14, Volume: 23, Issue:20

    Topics: Angiotensin II; Female; Humans; Placenta; Placentation; PPAR gamma; Pregnancy; Receptor, Angiotensin, Type 1; Rosiglitazone; Trophoblasts

2022